Clinical Trial

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This trial is a multicenter, open-label, single-arm, dose-escalation and dose-expansion clinical trial. The dose was increased according to the "3 + 3" rule. Patients with previously untreated patients with CD20-positive DLBCL were selected to evaluate the safety, tolerance (DLT, MTD), pharmacokinetics, and anti-tumor activity of TRS005 in combination with standard doses of cyclophosphamide, doxorubicin, and prednisone（T-CHP） by intravenous drip every 3 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-23.
Trial Details
NCT Number NCT07035379
Lead Sponsor Zhejiang Teruisi Pharmaceutical Inc.
Conditions Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment 66 participants
Start Date 2025-09-01
Primary Completion 2026-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-22